menu
    • menu
    [{"orgOrder":0,"company":"Pharmadax","sponsor":"Glia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Pro-Ocular","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharmadax \/ Glia","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Glia"},{"orgOrder":0,"company":"Pharmadax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"99m-Tc H7ND","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmadax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Undisclosed"},{"orgOrder":0,"company":"Pharmadax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"99m-Tc H7ND","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmadax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmadax

    Menu

    Pharmadax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmadax

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed

                            Pharmadax

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc H7ND

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            99mTc-H7ND Injection Diagnostic Safety & Efficacy In GI Tumor Peritoneal Metastasis

                            Details : 99m-Tc H7ND is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            August 06, 2025

                            Lead Product(s) : 99m-Tc H7ND

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmadax

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed

                            Pharmadax

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc H7ND

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers

                            Details : 99m-Tc H7ND is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 05, 2024

                            Lead Product(s) : 99m-Tc H7ND

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmadax

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed

                            Pharmadax

                            Taiwan arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pro-Ocular

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Glia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Dry Eye Disease Using Pro-ocularâ„¢ - A Proof of Concept, Safety, and Efficacy Study

                            Details : Pro-Ocular is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            May 12, 2021

                            Lead Product(s) : Pro-Ocular

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Glia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth